The global diabetes market is experiencing a surge driven by the increasing prevalence of this chronic disease. At the forefront of this evolution are leading developers of GLP-1 receptor agonists, a class of drugs https://tirzepatidepharma.com/index.php/product/eflornithine-13-9-gel/